Bone Marrow-Derived Cell Therapy Plus Core Decompression Enhanced Efficacy Compared With Core Decompression Alone in Treating Osteonecrosis of the Femoral Head: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Xiao-Na Xiang, Hao-Nan Wang, Hong-Chen He et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of bone marrow-derived cell therapy combined with core decompression versus core decompression alone in treating osteonecrosis of the femoral head. Analyzing data from ten randomized controlled trials involving 460 participants, the study found that the combination therapy significantly improved pain relief (SMD: -1.30) and hip function (SMD: -1.79), and enhanced joint survival (RR: 0.47).
Key findings
- Cell therapy plus core decompression improved pain relief (SMD: -1.30; 95% CI: -2.21 to -0.38).
- Hip function was significantly better with the combination therapy (SMD: -1.79; 95% CI: -1.79 to -0.90).
- Joint survival rates were higher with the combination therapy (RR: 0.47; 95% CI: 0.27-0.82).
- No significant differences in adverse events or radiographic progression were observed between groups.
Why it matters
The findings suggest that combining bone marrow-derived cell therapy with core decompression may enhance treatment outcomes for patients with osteonecrosis of the femoral head, potentially leading to improved pain management and joint preservation.